Q-omics provides the consensus-scored KRT83 profile across patient tissues and cancer cell-line models. KRT83 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, KRT83 is differentially expressed in 10, with the highest sampling consensus in LUAD. Additionally, KRT83 RNA expression shows 7,676 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight LUAD, and TGCT as cancer lineages where KRT83 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KRT83 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KRT83 survival associations across molecular data types. KRT83 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KRT83 RNA expression–survival associations across cancer types. High KRT83 expression shows unfavorable associations in LUAD, MESO, PAAD, UCEC and SCLC, but favorable associations in ESCA. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify LUAD as the clearest survival context for KRT83 RNA expression.
This table summarizes KRT83 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for KRT83. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KRT83 shows lower tumor expression in THCA and BRCA and higher tumor expression in LUAD, COAD, LUSC and KIRP. The LUAD box plot shows higher KRT83 RNA expression in tumor versus normal tissue (log2 FC = +1.306, t-test p < 0.001).
This table shows molecular features associated with KRT83 in patient tissues and cancer cell lines. In patient samples, KRT83 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, KRT83 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and OVARY.
